This guide explains current Parkinson's care through the American Parkinson Disease Association (APDA), a nationwide nonprofit founded in 1961 that funds research and provides support and education. For 2026, it focuses on proven drug options, newer approvals, and safety steps for motor symptoms and daily function. Parkinson's affects movement, balance, and daily tasks, and treatment choices change as symptoms change.
The University of California reports about 1 million Americans and more than 10 million people worldwide live with Parkinson's, with about 60,000 new U.S. diagnoses yearly University of California news page. Most diagnoses occur after age 60 and slightly more often in men.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What help can APDA offer?
- How do early motor treatments compare?
- What is new for OFF periods and advanced symptoms?
- What safety risks need a plan?
- How do stimulation and exercise fit daily care?
What help can APDA offer?
APDA provides chapters, Information and Referral Centers, education programs, and research funding. In its June 2026 public comment letter, APDA described over $313 million invested and listed its helpline at 800-223-2732.
A reader can use APDA for practical next steps after diagnosis or when treatment stops working well. Contact a local chapter or Information and Referral Center for referrals. Call the helpline for education about symptoms, drugs, and caregiving resources.
How do early motor treatments compare?
The American Academy of Neurology advises counseling before starting levodopa, dopamine agonists, or MAO-B inhibitors for early motor symptoms. Counseling covers expected benefit, side effects, and long-term movement problems.
This talk matters because no single starter drug fits every person. Work schedule, sleep, blood pressure, memory, and fall risk shape the choice. Ask what OFF periods look like, what dyskinesia looks like, and when to report either change.
📨 Get Free Parkinson's Guides Alerts
Free · No spam · Unsubscribe anytime
What is new for OFF periods and advanced symptoms?
AbbVie reported FDA approval of JUVMO, or tavapadon, on Sept. 25, 2026 as a once-daily oral selective D1/D5 agonist for adults with Parkinson's, usable alone or with levodopa PR Newswire report via Morningstar. The company said availability was expected in October 2026 after Phase 3 TEMPO trials.
APDA described tavapadon as another motor-symptom option across stages, alongside levodopa products including extended-release Crexont approved in August 2024. For advanced motor fluctuations, NeurologyLive reported FDA approval of Vyalev, or foscarbidopa and foslevodopa, in October 2024. It is a 24-hour continuous under-the-skin infusion based on levodopa. Medicare coverage was expected in 2025.
What safety risks need a plan?
Dopamine agonists can cause impulse-control disorders, hallucinations, daytime sleepiness, and low blood pressure on standing. Citeline reported that FDA ordered stronger safety labeling for these drugs, but not a boxed warning Citeline safety-labeling report.
Watch for these warning signs in the person taking the drug and in family reports: Tell the prescribing clinician quickly if any sign appears. Do not stop a Parkinson's drug suddenly without medical direction.
- new gambling urges, shopping sprees, binge eating, or hypersexuality
- seeing things that are not there, severe sleepiness, faintness, or falls after standing
- stronger symptoms after a dose change or added sleep drug
How do stimulation and exercise fit daily care?
Deep brain stimulation can improve tremor, rigidity, and slowness. Freezing of gait and falls still cause major disability for many patients.
UCSF reported a June 2026 adaptive system that adjusted stimulation in real time to movement patterns to ease gait UCSF news report. Exercise focused on balance, leg strength, and freezing of gait helps most when started early. A randomized trial by Canning and colleagues found about 70% fewer falls in milder disease with minimally supervised training, but no fall reduction in severe disease.
- start a balance and leg-strength plan soon after gait changes appear
- add freezing-of-gait drills, home hazards review, and walking-aid fitting
- use fall precautions from the first session, especially for severe disease
You Might Also Like
- Ozzy Osbourne Parkinson’s Guide 2026: Evidence, Options, and Safety
- Parkinson’s Disease Explained for 2026: Who It Affects, Key Evidence, and What to Do Next
- How to Verify Parkinson’s Disease Claims in 2026: NIH, FDA, and trial records, Evidence, and Red Flags